WO2011013646A1 - Produit pharmaceutique pour la prévention et le traitement de la sclérose latérale amyotrophique - Google Patents

Produit pharmaceutique pour la prévention et le traitement de la sclérose latérale amyotrophique Download PDF

Info

Publication number
WO2011013646A1
WO2011013646A1 PCT/JP2010/062580 JP2010062580W WO2011013646A1 WO 2011013646 A1 WO2011013646 A1 WO 2011013646A1 JP 2010062580 W JP2010062580 W JP 2010062580W WO 2011013646 A1 WO2011013646 A1 WO 2011013646A1
Authority
WO
WIPO (PCT)
Prior art keywords
adar2
interferon
site
glur2
gene
Prior art date
Application number
PCT/JP2010/062580
Other languages
English (en)
Japanese (ja)
Inventor
伸 郭
雄也 山下
拓人 日出山
Original Assignee
国立大学法人 東京大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人 東京大学 filed Critical 国立大学法人 東京大学
Publication of WO2011013646A1 publication Critical patent/WO2011013646A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Definitions

  • the present invention relates to a medicament for the prevention and / or treatment of amyotrophic lateral sclerosis.
  • Amyotrophic lateral sclerosis (amyotrophic lateral sclerosis, which may be abbreviated as ⁇ ALS '' in this specification) is a neurodegenerative disease whose cause of motor neuron selective degeneration has not been clarified. It causes progressive and severe muscle atrophy and weakness that begins without trigger. The disease is extremely fast, with more than half of patients dying from respiratory muscle paralysis within 3 years of onset. About 2 people per 100,000 people a year (especially 20-30 people over 60 years old) develop and it is not a rare disease, but effective treatment has been established at present. Absent.
  • causative ALS which accounts for about 10% of ALS
  • the causative gene has been identified as part of it.
  • autosomal dominant ALS1 has a mutation in SOD1 (superoxide dismutase 1 gene) on chromosome 21, and this causative gene is said to occupy about 20% of hereditary ALS.
  • SOD1 superoxide dismutase 1 gene
  • the development of drugs for ALS has been carried out mainly using mutant SOD1 transgenic animals, which are animal models of familial ALS.
  • about 90% of ALS is sporadic ALS that is not heritable, and this sporadic ALS may develop by a mechanism that is essentially different from familial ALS. Research is unlikely to produce effective medicines for sporadic ALS, which accounts for the majority of ALS.
  • the Q / of GluR2 one of the subunits that form the AMPA receptor glutamate receptor subtype by reducing the activity of the RNA editing enzyme ADAR2 (adenosine deaminase acting on RNA type 2) Since RNA editing that should not occur naturally at the R site does not occur, this sporadic ALS disease-specific molecular change is not found in familial ALS due to mutation SOD1, but is found disease-specific in sporadic ALS It has been suggested that this decrease in ADAR2 activity is a direct cause of motor neuron death. In motor neurons, it was also revealed that when the RNA editing rate of the GluR2 Q / R region is less than 100%, the neuron falls slowly. Therefore, it is considered that sporadic ALS can be treated by activating ADAR2 activity in motor neurons and restoring the RNA editing rate of the GluR2 Q / R site to 100%.
  • ADAR2 adenosine deaminase acting on RNA type 2
  • the present inventors have succeeded in establishing a cultured cell TetHeLaG2m cell capable of efficiently screening a substance having an ADAR2 activity stimulating action, and using this cell, several antidepressants such as imipramine have been used for ADAR2 activity in motor neurons. (Neurosci. Res., 64, pp.251-258, 2009). However, there is no suggestion or teaching in the above publications about the possibility that other drugs have the activity of activating ADAR2. In addition, the present inventors have reported that K / E sites of cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2) RNA undergo ADAR2-specific RNA editing using cultured cells (Neurosci.
  • CYFIP2 cytoplasmic fragile X mental retardation protein interacting protein 2
  • ADAR2 knockout mouse brain homogenate has also been reported to specifically reduce editing at this site, and it has been confirmed that in vivo has similar activity. (RNA, 14, pp.1110-1118, 2008).
  • An object of the present invention is to provide a medicament having ADAR2 activity activation action in motor neurons and useful for prevention and / or treatment of sporadic ALS.
  • the present inventors conducted intensive research to solve the above problems, screened substances having an action to activate ADAR2 activity in motor neurons using TetHeLaG2m cells, and obtained several new candidate substances.
  • the present inventors have shown that ADAR2 activity in motor neurons increases when an antidepressant having ADAR2 activity stimulating action is systemically administered to wild-type mice, using ADAR2 -specific substrate CYFIP2 to RNA at K / E site It was clarified from the increase in the editing rate, and by applying this method to the above-mentioned candidate compounds, it was confirmed that these candidate compounds have an ADR2 activity activating action even in an in vivo test.
  • the present inventors have found that a 50% decrease in ADAR2 activity causes motoneuron death via RNA editing abnormalities in the GluR2 Q / R region based on analysis of mice that are conditionally knocked out so that the ADAR2 gene becomes heterozygous. Based on this finding, it was confirmed that the above candidate compounds obtained by screening increase the RNA editing rate of GluR2 Q / R site in ADAR2 conditional mouse heterozygotes. Is useful as an active ingredient of a medicine for prevention and / or treatment of sporadic ALS. The present invention has been completed based on the above findings.
  • sporadic muscle comprising as an active ingredient a substance selected from the group consisting of (a) leucomycins and oleandomycins, (b) cyclophosphamides, and (c) interferon ⁇ s.
  • a medicament for the treatment and / or prevention of amyotrophic lateral sclerosis is provided.
  • the aforementioned medicament wherein the oleandomycins are roxithromycin, a salt thereof, or an ester thereof; the leucomycins are leucomycin A 3 (josamycin), a salt thereof, or an ester thereof.
  • the above drugs the above drug in which the cyclophosphamide is cyclophosphamide or 4-hydroxycyclophosphamide; and the interferon ⁇ is interferon ⁇ , interferon ⁇ -2a, interferon ⁇ -2b, or
  • the above-mentioned medicament which is a polyoxyethylene glycol derivative is provided.
  • the present invention provides a method for screening a substance useful as an active ingredient of a medicament for the treatment and / or prevention of sporadic amyotrophic lateral sclerosis, comprising heterozygous ADAR2 conditional
  • a method comprising the step of selecting, as a candidate compound, a substance that increases the RNA editing rate of a GluR2 Q / R site in a knockout animal, preferably a heterozygous ADAR2 conditional knockout mouse.
  • a substance that increases the RNA editing rate at the K / E site of ADAR2 -specific substrate CYFIP2 in a wild-type animal, preferably a wild-type mouse is selected as a candidate compound.
  • a method comprising the steps of:
  • the above heterozygous ADAR2 conditional knockout animal is also provided by the present invention. According to a preferred embodiment of this animal, it has a heterozygous gene having a LoxP site inserted so as to sandwich exons 7, 8, and 9 encoding the active group of mouse ADAR2 gene adarb1, There is provided the above conditional knockout animal expressing Cre recombinase; the above conditional knockout animal expressing Cre recombinase in a timed manner specifically in motor neurons.
  • the animal is preferably a mouse, and more preferably a mouse that expresses Cre recombinase depending on the promoter of the vesicular acetylcholine transporter.
  • the present invention also provides heterozygous ADAR2 conditional knockout animals for use in the above screening.
  • the medicament provided by the present invention has ADAR2 activity activation action in motor neurons and is useful for prevention and / or treatment of sporadic amyotrophic lateral sclerosis.
  • ADAR2 activity activation action in motor neurons and is useful for prevention and / or treatment of sporadic amyotrophic lateral sclerosis.
  • This figure shows the results of measuring the RNA editing rate of RK / E site of ADAR2-specific substrate CYFIP2 in spinal single motor neurons after whole-body administration of josamycin, cyclophosphamide, and interferon ⁇ for 7 days to wild-type mice. is there.
  • 1) is the average value of the editing rate of all samples
  • 2) is the percentage of samples whose editing rate was 100%
  • 3) is the neuron whose editing rate is 100% calculated from 2) above.
  • the predicted value of the percentage of It is the conceptual diagram which showed the production method of a heterojunction ADAR2 conditional knockout mouse.
  • the upper figure of 1) shows the gene structure in which the LoxP site is inserted into intron 6 and intron 9 with the active group (deaminase) part of the adarb1 gene in between, and the result of confirming the genotype of the resulting genetically modified mouse by PCR Is shown in the figure below.
  • Fig. 2 (1) Bottom 2) Mutant mouse VAChT-Cre., Which expresses Cre recombinase depending on the promoter of vesicular acetylcholine transporter. Fast and VAChT-Cre. It is the figure which showed the expression of the motor neuron specific Cre recombinase in Slow.
  • FIG. 6 shows progressive motor neuron death in Fast mice. It is the figure which showed that a motor neuron death was blocked
  • FIG. 4 shows that GluR2 RNA editing is reduced and motor neuron death is caused by halving ADAR2 activity.
  • the medicament of the present invention is a medicament for the treatment and / or prevention of ALS, and comprises (a) leucomycins and oleandomycins, (b) cyclophosphamides, and (c) interferon ⁇ s. It contains a substance selected from the group as an active ingredient.
  • the medicament of the present invention can be applied to sporadic ALS, but may be effective when administered to familial ALS.
  • Natural or semi-synthetic leucomycins can be used as the leucomycins, but typically, for example, leucomycin (LM: sometimes referred to as kitasamycin) A 1 , A 3 (josamycin), A 4 , A 5 , A 6 , A 7 , A 8 , and A 9 , and any mixtures thereof.
  • leucomycin sometimes referred to as kitasamycin
  • SPM spiramycin
  • MDM midecamycin
  • physiologically acceptable salts of these leucomycins or their esters can be used.
  • ester of leucomycin examples include josamycin propionate, 3 "-O-propionylleucomomycin (rokitamicin: RKM), acetylspiramycin I, II, or III, and midecamycin acetate.
  • Physiologically acceptable salts include, for example, mineral salts such as hydrochloride, sulfate and phosphate, organic acid salts such as tartrate, maleate and malate.
  • the leucomomycins may be hydrates or solvates of a free form substance or a salt thereof or an ester thereof.
  • leucomycin A 3 josamycin
  • josamycin propionate particularly preferably leucomycin A 3 It is.
  • leucomycins that can be used as the active ingredient of the medicament of the present invention is shown below, but the active ingredient of the medicament of the present invention is not limited to these leucomycins (Source: “Today's New Drug— “Transition of modern pharmaceuticals", by Saburo Fukai, published by Yakuho Hokpo, Inc., March 15, 1995, p. 903).
  • Leucomycins are classified as 16-membered ring macrolides, but macrolides (but excluding bafilomycin) included in 16-membered ring macrolides may be used as the active ingredient of the medicament of the present invention. .
  • oleandomycins natural or semi-synthetic oleandomycins can be used. Typical examples include, but are not limited to, erythromycins (such as erythromycin A), roxithromycin, clarithromycin, and oleandomycin. Furthermore, physiologically acceptable salts of these oleandomycins, or esters thereof can be used.
  • esters of oleandomycins include, but are not limited to, erythromycin propionate, erythromycin estrate, triacetyloleandomycin (troleandomycin), and the like.
  • physiologically acceptable salts include, but are not limited to, the salts mentioned for the above leucomycins.
  • oleandomycins a hydrate or solvate of a free form substance or a salt thereof or an ester thereof may be used.
  • roxithromycin is preferable.
  • oleandomycins that can be used as the active ingredient of the pharmaceutical agent of the present invention is shown below, but the active ingredient of the pharmaceutical agent of the present invention is not limited to these oleandomycins (Source: “Today's New drug-transition of modern pharmaceuticals ", Saburo Fukai, published by Yakuho Hokpo, Inc., March 15, 1995, page 899). Although oleandomycins are classified as 14-membered ring macrolides, the macrolides included in the 14-membered ring macrolides may be used as the active ingredient of the medicament of the present invention.
  • cyclophosphamides include oxaazaphosphorine compounds having a bis (2-chloroethyl) amino group, such as cyclophosphamide or its active metabolite 4-hydroxycyclophosphamide, ifosfamide. Of these, cyclophosphamide is preferred. Hydrates or solvates may be used as the cyclophosphamides.
  • interferon ⁇ s isoforms IFN- ⁇ 1, ⁇ 2, ⁇ 4, ⁇ 5, ⁇ 6, ⁇ 7, ⁇ 8, ⁇ 10, ⁇ 13, ⁇ 14, ⁇ 16, ⁇ 17, and ⁇ 21 and their are known, for example, interferon ⁇ , interferon ⁇ 2a, interferon ⁇ 2b and the like are preferably used.
  • interferon ⁇ s in addition to interferon ⁇ derived from cultured lymphocytes, interferon ⁇ s produced by gene recombination may be used.
  • polyethylene glycol (PEG) derivatives of interferon ⁇ are also provided for the purpose of extending the action time in the body, but such derivatives may be used as the active ingredient of the medicament of the present invention.
  • PEG polyethylene glycol
  • the medicament when a medicament containing the above active ingredient is already marketed, the medicament can be used as it is as a medicament of the present invention.
  • the active ingredient can be combined with an appropriate formulation additive, and can be prepared and administered as a pharmaceutical composition for oral administration or parenteral administration depending on the type of the active ingredient.
  • leucomycins are preferably provided as a pharmaceutical composition for oral administration or as a pharmaceutical composition for parenteral administration (for example, intravenous administration), and for cyclophosphamides, a pharmaceutical composition for oral administration.
  • the interferon ⁇ is preferably provided as a pharmaceutical composition for parenteral administration (preferably for intramuscular administration).
  • a pharmaceutical composition for parenteral administration for example, intravenous administration
  • the interferon ⁇ is preferably provided as a pharmaceutical composition for parenteral administration (preferably for intramuscular administration).
  • the kind of pharmaceutical composition for oral administration is not specifically limited, For example, a tablet, a capsule, etc. can be mentioned.
  • the medicament of the present invention has ADAR2 activity activation action in motor neurons, and is particularly useful for the prevention and / or treatment of sporadic amyotrophic lateral sclerosis among amyotrophic lateral sclerosis.
  • the medicament of the present invention suppresses the reduction in RNA editing rate of GluR2 Q / R site due to decreased ADAR2 activity and / or increases the RNA editing rate of GluR2 Q / R site Can be made.
  • prevention mainly means prevention of the onset of ALS
  • treatment mainly refers to prevention of progression of various symptoms in ALS, or relief or remission of various symptoms in ALS. Although meant, these terms should not be construed as limiting in any way, but in the broadest sense.
  • the medicament of the present invention can be applied to, for example, ALS with dementia.
  • the action of the medicament of the present invention can be confirmed, for example, by the method specifically shown in the following examples.
  • the method for confirming in vitro the effect of the pharmaceutical of the present invention on the RNA editing rate of the GluR2 Q / R site was specifically shown in Neurosci.NRes., 64, pp.251-258, 2009, for example.
  • a method using cultured cells TetHeLaG2m cells can be employed.
  • ADAR2 activity activation action in vivo is, for example, (a) that the ADAR2 activity in motor neurons is increased when the pharmaceutical of the present invention is systemically administered using a wild-type mouse, the ADAR2 specific substrate CYFIP2 A method of confirming from an increase in the RNA editing rate at the K / E site; and (b) the ADAR2 activity of spinal motor neurons is increased by the medicament of the present invention using an animal that is conditionally knocked out to be heterozygous for ADAR2. And a method for confirming that motor neuron death is suppressed can be employed.
  • the type of model animal is not particularly limited, but preferably a heterozygous ADAR2 conditional knockout mouse or the like can be mentioned, and the specific production method is specifically shown in the Examples.
  • the dose of the medicament of the present invention is not particularly limited, but for leucomycins and oleandomycins, about 100 to 2,000 mg for oral administration and about 50 to 1,000 mg for parenteral administration such as intravenous administration.
  • cyclophosphamide is about 10 to 500 mg for oral administration, about 1 to 200 mg for parenteral administration such as intravenous administration, and 100 mg for parenteral administration such as intramuscular administration for interferon ⁇ . About 10 to 20 million international units.
  • the dose is not limited to the above range, and can be appropriately selected according to the age and weight of the patient, the purpose of prevention or treatment, the degree of symptoms, and the like.
  • the administration route is not limited to the routes exemplified above, and it is needless to say that an appropriate administration route can be selected according to the type of active ingredient.
  • in vivo screening for a test compound using an animal that has been conditionally knocked out to be heterozygous for ADAR2, preferably a heterozygous ADAR2 conditional knockout mouse Can be used to select candidate compounds that increase ADAR2 activity in neurons, preferably brain, spinal cord, and motor neurons, by increasing the RNA editing rate of the GluR2 Q / R site. Therefore, it becomes possible to obtain a new active pharmaceutical ingredient having a preventive and / or therapeutic effect.
  • this heterozygous knockout animal in addition to the above-mentioned measurement of the editing rate, it is possible to measure the inhibitory effect of the test compound on neuronal cell death. It is also possible to confirm the morphological measurement of the number of axons, the reduced expression of specific cell death markers by Western blotting, and the like.
  • a gene in which a LoxP site is inserted so as to sandwich an exon of the ADAR2 gene is introduced into an animal embryo, and a heterozygous gene-modified animal is prepared through a chimeric animal, for example, exercise.
  • a conditional knockout animal can be created by crossing a mutant animal that expresses Crerecombinase (Cre) in neurons in a timely manner with the above gene mutant animal. This technique is well known to those skilled in the art, and can be performed with appropriate alterations or modifications.
  • the test compound was administered to wild-type mice, and RNA at the K / E site of CYFIP2 which is a specific substrate for ADAR2
  • RNA at the K / E site of CYFIP2 which is a specific substrate for ADAR2
  • RNA editing rate of the GluR2 Q / R site is specifically catalyzed by ADAR2.
  • TetHeLaG2m cells (Neurosci. Res., 64, pp.251-258, 2009) were used as a culture system for measuring the RNA editing activity of the GluR2 Q / R site of ADAR2.
  • This cell is obtained by introducing a mini GluR2 gene consisting of exon 11 containing the Q / R site of the GluR2 gene, a part of intron 11 containing the sequence ECS complementary to the Q / R site, and exon 12 into TetHeLa cells.
  • This is a cell line obtained by cloning a cell line that stably expresses the mini-GluR2 gene and has an editing rate of about 50% in its Q / R site.
  • Example 2 Wild-type mice (C57Bl / 6J strain, male, 16 weeks old, average body weight 20 g) were administered systemically for 7 days with josamycin, cyclophosphamide, and interferon ⁇ , and then the ADAR2-specific substrate CYFIP2 The K / E site RNA editing rate was measured. Each test drug is administered subcutaneously to mice (100 mg, 20 mg, and 1,000,000 units per kg body weight as daily dose), and the brain and spinal cord of the mouse is removed after decapitation, and total RNA is extracted by a standard method did. After RT-PCR, the RNA editing rate of the K / E site was calculated by quantifying the digested fragment obtained by treating the product with the restriction enzyme MseI.
  • Table 2 shows the results of measuring the RNA K / E site RNA editing rate of the ADAR2-specific substrate CYFIP2 for the mouse brain administered with each drug.
  • a single motor neuron was excised from the spinal cord of the same individual using a laser microdissector, and the RNA obtained from three neurons was taken as one sample.
  • the result of editing rate in 20 samples) is shown in Fig. 1 as a scatter diagram.
  • 1) is the average editing rate for all samples
  • 2) is the percentage of samples where the editing rate was 100%
  • 3) is the neuron whose editing rate was calculated from 2) above.
  • the predicted value of the percentage of The arrow indicates the sample whose edit rate was 100%.
  • Example 3 (a) Preparation of a conditional ADAR2 knockout mouse A LoxP site ( ⁇ ) was inserted into intron 6 and intron 9 so as to sandwich the active group (deaminase) part of the adarb1 gene, which is a 129 / SvEv mouse homologous gene of ADAR2 gene (Fig. 2 (1) top) and a vector in which a neomycin resistance gene (Neo) sandwiched between FRT sites as a selection cassette was inserted into intron 9 was constructed using pBluescript SKII (-). The nucleic acid sequence of the mouse adarb1 gene into which LoxP and Neo-PLUS selection cassete are inserted is shown in FIG.
  • the obtained gene was introduced into morulas derived from C57BL / 6 mice by a conventional method, and knockout mice were prepared via chimeric mice. The genotype was confirmed by PCR (FIG. 2 (1) lower diagram).
  • VAChT-Cre that expresses Cre recombinase (Cre) in a promoter-dependent manner in the vesicular acetylcholine transporter. Fast and VAChT-Cre.
  • the ADAR2 flox / flox / VAChT-Cre.Fast mouse and the ADAR2 flox / flox / VAChT-Cre.Slow mouse were obtained by crossing Slow with the ADAR2 flox / flox mouse obtained above.
  • VAChT-Cre mice express Cre recombinase selectively in motor neurons, but in the Fast system, it is expressed in 40-70% of motor neurons by 5 weeks of age, and in the Slow system, about 50% of motor neurons at 8 months of age. It is expressed (Fig. 2 (2)).
  • ADAR2 flox / flox / VAChT-Cre mice When the anterior horn of the spinal cord of 6-month-old ADAR2 flox / flox / VAChT-Cre mice was examined by in situ hybridization, in the wild type (Ctl), the ADAR2 gene was expressed in all motor neurons. ADAR2 flox / flox / VAChT-Cre mice were deficient in ADAR2 gene expression in some motor neurons (upper left in FIG. 4). Furthermore, when the motor neuron was cut out and the RNA editing rate of the Q / R region of GluR2 mRNA was measured, the editing rate was 0% for the motor neuron lacking ADAR2, and the editing rate was 100% for the motor neuron expressing ADAR2. It was confirmed that ADAR2 activity was inactivated. We also confirmed that this gene knockout is Cre-dependent.
  • Figure 5 shows the RNA editing rate of the GluR2 Q / R region measured by RT-PCR and restriction enzyme treatment using three 2-month-old ADAR2 flox / flox /VAChT-Cre.Fast mouse motoneurons as one sample. Shown in The horizontal axis represents the RNA editing rate of the GluR2 Q / R site, and the vertical axis represents the number of samples. In addition to samples with 0% editing rate and 100% samples, the presence of around 30% and around 70% samples was also observed. Since the edit rate of neurons lacking ADAR2 is 0%, the 0% group means that ADAR2 is missing in all three neurons in one sample (0: 3), and 100% The group means that ADAR2 is expressed in all neurons (3: 0).
  • the middle sample means that ADAR2 is expressed only in 2 out of 3 neurons (1: 2) or 1 neuron (2: 1).
  • ADAR2 was knocked out Cre-dependently in the group with an editing rate of 0%.
  • Ctl1 shows the results of ADAR2 flox / flox mice
  • Ctl2 shows the results of VAChT-Cre.Fast mice.
  • FIG. 6 shows ADAR2 flox / flox / VAChT-Cre. It showed progressive motor neuron death in Fast mice.
  • spinal cord morphology ADAR2 expression was deficient in some large anterior horn cells, and motor neurons with air bubbles in the cytoplasm were observed.
  • the anterior spinal cord atrophy, axonal degeneration and a decrease in the number of axons were observed, the number of large anterior horn cells (AHC) decreased progressively after 2 months of age, especially only those cells that did not express ADAR2.
  • Figure 6, lower left The immune activity of GFAP (astrocyte marker) increased with age, indicating that astrocytes are reactively proliferating with the loss of neurons.
  • the microglia marker MAC2 is most prominent at 6 months, indicating that the response of microglia accompanying cell death is strongest at this time.
  • the Q / R site is glutamine (CAG) in the GluR2 gene that expresses edited GluR2 without ADAR2 activity.
  • CAG glutamine
  • GluR-B mice whose genes were modified to encode arginine (CGG)
  • ADAR2 flox / flox / VAChT-Cre.Fast mice were crossed.
  • ADAR2 flox / flox / VAChTCre.Fast / GluR-B (R / R) mice were examined.At 6 months of age, ADAR2 flox / flox / VAChT-Cre.Fast mice (Fig. In A) of 7), more than 40% of motor neurons dropped out, and Rotarod score and arm grip strength decreased significantly, whereas ADAR2 flox / flox x / VAChT-Cre.Fast / GluR-B (R / R) Mice (A / G) showed no changes in the number of motor neurons and behavior compared to control mice. Therefore, it became clear that the GluR2 Q / R site was the only RNA editing abnormality caused by ADAR2 deficiency that involved motor neuron death.
  • RNA editing rate of GluR2 Q / R site in motor neurons of heterozygous ADAR2 flox / + /VAChT-Cre.Fast mice knocked out only one of ADAR2 gene was less than 100% in about 20% motor neurons Met.
  • the control group shows 100% editing rate in all motor neurons, so about half of the motor neurons expressing only one ADAR2 gene in heterozygous mice have decreased ADAR2 activity, and complete RNA editing at this site. It became clear that there was no.
  • this hetero mouse is a model reflecting the molecular pathology of sporadic ALS, and was shown to be useful as a drug development tool for the prevention and / or treatment of ALS aimed at activating ADAR2 activity.
  • Example 4 The ADAR2 heterozygote ADAR2 flox / + /VAChT-Cre.Fast mouse obtained in Example 3 was administered systemically with josamycin, cyclophosphamide, and interferon ⁇ in the same manner as in Example 2 for 7 days.
  • the RNA editing rate at the Q / R site was measured.
  • the results are shown in Table 3 below as the average value ⁇ standard deviation of 60 individuals in each group of 3 individuals. From these results, it was confirmed that josamycin, cyclophosphamide, and interferon ⁇ all have an action of increasing the RNA editing rate of the GluR2 Q / R site in mouse neurons.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

L'invention porte sur un produit pharmaceutique pour la prévention et le traitement de la sclérose latérale amyotrophique sporadique, lequel produit contient, comme principe actif, une substance qui est choisie dans le groupe constitué par (a) les leucomycines et les oléandomycines, (b) les cyclophosphamides et (c) les interférons a, ladite substance ayant un effet d'activation de l'activité de l'ADAR2 dans les motoneurones.
PCT/JP2010/062580 2009-07-28 2010-07-27 Produit pharmaceutique pour la prévention et le traitement de la sclérose latérale amyotrophique WO2011013646A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009175128A JP2012197229A (ja) 2009-07-28 2009-07-28 筋萎縮性側索硬化症の予防及び治療のための医薬
JP2009-175128 2009-07-28

Publications (1)

Publication Number Publication Date
WO2011013646A1 true WO2011013646A1 (fr) 2011-02-03

Family

ID=43529301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/062580 WO2011013646A1 (fr) 2009-07-28 2010-07-27 Produit pharmaceutique pour la prévention et le traitement de la sclérose latérale amyotrophique

Country Status (2)

Country Link
JP (1) JP2012197229A (fr)
WO (1) WO2011013646A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099368A1 (fr) * 2017-11-16 2019-05-23 Levetan Claresa Compositions et méthodes pour traiter ou prévenir le diabète de type 1 en utilisant un modificateur de la réponse biologique en association avec une ou plusieurs thérapies de type régénération ou remplacement d'îlots de langerhans ou de cellules bêta

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047206A (ja) * 2000-07-28 2002-02-12 Taisho Pharmaceut Co Ltd Ｇｄｎｆ産生促進剤、パーキンソン病治療剤およびａｌｓ治療剤
WO2004035053A1 (fr) * 2002-10-15 2004-04-29 Fujisawa Pharmaceutical Co., Ltd. Promoteur de production du facteur neurotrophique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047206A (ja) * 2000-07-28 2002-02-12 Taisho Pharmaceut Co Ltd Ｇｄｎｆ産生促進剤、パーキンソン病治療剤およびａｌｓ治療剤
WO2004035053A1 (fr) * 2002-10-15 2004-04-29 Fujisawa Pharmaceutical Co., Ltd. Promoteur de production du facteur neurotrophique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SHIN KAKU: "Kokoro no Kenko Kagaku Kenkyu Jigyo 'Kin Ishukusei Sokusaku Kokasho ni Taisuru Tokui Chiryoho no Kaihatsu'", KOSEI RODO KAGAKU KENKYU SEIKA DATABASE GAIYOBAN, 2008, Retrieved from the Internet <URL:http://mhlw-grants.niph.go.jp/niph/search/NIDDOO.do> [retrieved on 20100831] *
YASUHIRO NAKAHARA: "Zaitaku Nanbyo Kanja san no Tameno Kusuri no Chishiki [Dai 2 Kai] Kin Ishukusei Sokusaku Kokasho Chiryozai Riluzole", NANBYO TO ZAITAKU CARE, 2001 NEN 2 GATSU, vol. 6, pages 40 - 41 *
YASUO IWASAKI ET AL.: "Tokushu/Kin Ishukusei Sokusaku Kokasho no Saishin Chiryo Joho [Dai 4 Bu] Riluzole Ninka Go no Saishin'yaku Joho", NANBYO TO ZAITAKU CARE, 2000 NEN 10 GATSU, vol. 6, no. 7, pages 20 - 23 *
YUYA YAMASHITA ET AL.: "'ALS Kikin' Kenkyu Shoreikin Kenkyu Seika Hokokusho ''Kohatsusei ALS no Hassho ni Kansuru RNA Henshu Koso ADAR 2 Kassei no Chosetsu Kiko no Kaiseki''", NIPPON ALS KYOKAI HEISEI 20 NENDO 'ALS KIKIN' KENKYU SHOREIKIN KOFU TAISHO KENKYU SEIKA HOKOKUSHO (1), 3 July 2009 (2009-07-03), pages 1 - 22, Retrieved from the Internet <URL:http://www.alsjapan.org/contents2/info0/downloads/20_hokoku02.pdf> [retrieved on 20100813] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099368A1 (fr) * 2017-11-16 2019-05-23 Levetan Claresa Compositions et méthodes pour traiter ou prévenir le diabète de type 1 en utilisant un modificateur de la réponse biologique en association avec une ou plusieurs thérapies de type régénération ou remplacement d'îlots de langerhans ou de cellules bêta

Also Published As

Publication number Publication date
JP2012197229A (ja) 2012-10-18

Similar Documents

Publication Publication Date Title
US7592314B2 (en) Use of VEGF and homologues to treat neuron disorders
Kim et al. Axon regeneration in young adult mice lacking Nogo-A/B
Von Koch et al. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice
Andressoo et al. An Xpd mouse model for the combined xeroderma pigmentosum/Cockayne syndrome exhibiting both cancer predisposition and segmental progeria
US10918697B2 (en) Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
JP2021169461A (ja) 寿命に関する動物モデル並びに寿命を延ばす及び腫瘍化を阻害する関連方法
AU2001268968A1 (en) Use of VEGF and homologues to treat neuron disorders
US11351225B2 (en) Methods for modulating development and function of photoreceptor cells
Dragatsis et al. Huntingtin-associated protein 1 (Hap1) mutant mice bypassing the early postnatal lethality are neuroanatomically normal and fertile but display growth retardation
EP2471916A1 (fr) Marqueur pour diagnostic, procédé de diagnostic et agent thérapeutique pour la sclérose latérale amyotrophique, et modèle animal et modèle cellulaire développant une sclérose latérale amyotrophique
WO2011013646A1 (fr) Produit pharmaceutique pour la prévention et le traitement de la sclérose latérale amyotrophique
Ishiyama et al. Genetic transfer of the wobbler gene to a C57BL/6J× NZB hybrid stock: natural history of the motor neuron disease and response to CNTF and BDNF cotreatment
WO1996035785A9 (fr) ANIMAUX TRANSGENIQUES PRESENTANT UN GENE DU RECEPTEUR BETA DE L&#39;HORMONE THYROïDIENNE DEFECTUEUX
WO1996035785A2 (fr) ANIMAUX TRANSGENIQUES PRESENTANT UN GENE DU RECEPTEUR BETA DE L&#39;HORMONE THYROïDIENNE DEFECTUEUX
Ostedgaard et al. EXPRESSION AND LOCALIZATION OF PORCINE AIRWAY MUCINS
WO2002097079A2 (fr) Gene codant une nouvelle proteine de type moteur moleculaire et procede diagnostique pour une maladie liee a ce gene

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10804392

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10804392

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP